Exelixis Inc (EXEL) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-07-03..
Gross margin
Overview →Financial period ending 2026-07-03; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-07-03. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 2.44B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 85.67M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-07-03 | (m) | $2.44B | $85.67M | (m) |
| 2026-04-03 | (m) | $2.38B | $84.48M | (m) |
| 2026-01-02 | (m) | $2.32B | $83.70M | (m) |
| 2025-10-03 | (m) | $2.29B | $77.18M | (m) |
| 2025-07-04 | (m) | $2.23B | $75.94M | (m) |
| 2025-04-04 | (m) | $2.30B | $74.13M | (m) |
| 2025-01-03 | (m) | $2.17B | $76.22M | (m) |
| 2024-09-27 | (m) | $2.08B | $78.00M | (m) |
| 2024-06-28 | (m) | $2.01B | $79.45M | (m) |
| 2024-03-29 | (m) | $1.85B | $79.49M | (m) |
| 2023-12-29 | (m) | $1.83B | $72.55M | (m) |
| 2023-09-29 | (m) | $1.77B | $66.71M | (m) |
| 2023-06-30 | (m) | $1.71B | $63.24M | (m) |
| 2023-03-31 | (m) | $1.66B | $59.02M | (m) |
| 2022-12-30 | (m) | $1.61B | $57.91M | (m) |
| 2022-09-30 | (m) | $1.64B | $54.91M | (m) |
| 2022-07-01 | (m) | $1.55B | $51.48M | (m) |
| 2022-04-01 | (m) | $1.52B | $52.88M | (m) |
| 2021-12-31 | (m) | $1.43B | $52.87M | (m) |
| 2021-10-01 | (m) | $1.25B | $48.99M | (m) |
| 2021-07-02 | (m) | $1.16B | $45.84M | (m) |
| 2021-04-02 | (m) | $1.03B | $40.18M | (m) |
| 2021-01-01 | $705.28M | $987.54M | $36.27M | 71.42% |
| 2020-10-02 | (m) | $957.80M | $37.76M | (m) |
| 2020-07-03 | (m) | $998.41M | $36.57M | (m) |
| 2020-04-03 | (m) | $979.20M | $34.88M | (m) |
| 2020-01-03 | $726.85M | $967.77M | $33.10M | 75.11% |
| 2019-09-27 | (m) | $956.07M | $29.93M | (m) |
| 2019-06-28 | (m) | $909.76M | $29.75M | (m) |
| 2019-03-29 | (m) | $855.59M | $28.21M | (m) |
| 2018-12-28 | $592.93M | $853.83M | $26.35M | 69.44% |
| 2018-09-29 | (m) | (m) | (m) | (m) |
| 2018-09-28 | (m) | $745.30M | (m) | (m) |
| 2018-06-29 | (m) | $672.41M | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2018-03-30 | (m) | $583.94M | (m) | (m) |
| 2017-12-29 | $333.94M | $452.48M | (m) | 73.80% |
| 2017-09-30 | (m) | $409.99M | (m) | (m) |
| 2017-09-29 | $292.49M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $319.67M | (m) | (m) |
| 2017-03-31 | (m) | $256.91M | (m) | (m) |
| 2016-12-31 | $128.82M | $191.45M | (m) | 67.29% |
| 2016-12-30 | (m) | $191.45M | (m) | (m) |
| 2016-09-30 | (m) | $123.81M | (m) | (m) |
| 2016-07-01 | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $71.47M | (m) | (m) |
| 2016-04-01 | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $43.21M | (m) | (m) |
| 2016-01-01 | (m) | $37.17M | (m) | (m) |
| 2015-12-31 | $33.28M | $37.17M | (m) | 89.52% |
| 2015-09-30 | (m) | $34.59M | (m) | (m) |
| 2015-06-30 | $28.32M | $31.02M | (m) | 91.27% |
| 2015-03-31 | $27.09M | $29.59M | (m) | 91.55% |
| 2014-12-31 | $23.07M | $25.11M | (m) | 91.86% |
| 2014-09-30 | (m) | $22.11M | (m) | (m) |
| 2014-06-30 | (m) | $21.28M | (m) | (m) |
| 2014-03-31 | (m) | $26.57M | (m) | (m) |
| 2013-12-31 | $30.22M | $31.34M | (m) | 96.43% |
| 2013-09-30 | (m) | $34.80M | (m) | (m) |
| 2013-06-30 | (m) | $42.65M | (m) | (m) |
| 2013-03-31 | (m) | $38.61M | (m) | (m) |
| 2012-12-31 | (m) | $47.45M | (m) | (m) |
| 2012-09-30 | (m) | $132.94M | (m) | (m) |
| 2012-06-30 | (m) | $247.90M | (m) | (m) |
| 2012-03-31 | (m) | $272.25M | (m) | (m) |
| 2011-12-31 | (m) | $289.64M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $178.74M | (m) | (m) |
| 2010-12-31 | (m) | $185.04M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $151.76M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |